187 related articles for article (PubMed ID: 35887129)
1. FOXM1-CD44 Signaling Is Critical for the Acquisition of Regorafenib Resistance in Human Liver Cancer Cells.
Wuputra K; Hsiao PJ; Chang WT; Wu PH; Chen LA; Huang JW; Su WL; Yang YH; Wu DC; Yokoyama KK; Kuo KK
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887129
[TBL] [Abstract][Full Text] [Related]
2. Isovitexin reduces carcinogenicity and stemness in hepatic carcinoma stem-like cells by modulating MnSOD and FoxM1.
Cao X; Liu L; Yuan Q; Li X; Cui Y; Ren K; Zou C; Chen A; Xu C; Qiu Y; Quan M; Zhang J; Cao J; Chen X
J Exp Clin Cancer Res; 2019 Jun; 38(1):264. PubMed ID: 31208440
[TBL] [Abstract][Full Text] [Related]
3. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
Huang H; Hou J; Liu K; Liu Q; Shen L; Liu B; Lu Q; Zhang N; Che L; Li J; Jiang S; Wang B; Wen Q; Hu L; Gao J
J Gastroenterol Hepatol; 2021 Dec; 36(12):3429-3437. PubMed ID: 34258777
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 augments sorafenib resistance and promotes progression of hepatocellular carcinoma by epigenetically activating KIF23 expression.
Zhu C; Guo H; Ma Z; Shi S; Zhao X; Zhai D; Zhou X; Jiang P; Xu Q; Cai J
Biochem Biophys Res Commun; 2023 May; 656():1-9. PubMed ID: 36940637
[TBL] [Abstract][Full Text] [Related]
5. Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells.
Yan D; Yan X; Dai X; Chen L; Sun L; Li T; He F; Lian J; Cai W
Oncol Rep; 2019 Aug; 42(2):785-796. PubMed ID: 31233189
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 promotes proliferation in human hepatocellular carcinoma cells by transcriptional activation of CCNB1.
Chai N; Xie HH; Yin JP; Sa KD; Guo Y; Wang M; Liu J; Zhang XF; Zhang X; Yin H; Nie YZ; Wu KC; Yang AG; Zhang R
Biochem Biophys Res Commun; 2018 Jun; 500(4):924-929. PubMed ID: 29705704
[TBL] [Abstract][Full Text] [Related]
7. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.
Zhang B; Zhang Y; Zou X; Chan AW; Zhang R; Lee TK; Liu H; Lau EY; Ho NP; Lai PB; Cheung YS; To KF; Wong HK; Choy KW; Keng VW; Chow LM; Chan KK; Cheng AS; Ko BC
J Pathol; 2017 Dec; 243(4):418-430. PubMed ID: 28862757
[TBL] [Abstract][Full Text] [Related]
8. Downreguation of FoxM1 by miR-214 inhibits proliferation and migration in hepatocellular carcinoma.
Tian C; Wu H; Li C; Tian X; Sun Y; Liu E; Liao X; Song W
Gene Ther; 2018 Jul; 25(4):312-319. PubMed ID: 29973656
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 Is a Novel Molecular Target of AFP-Positive Hepatocellular Carcinoma Abrogated by Proteasome Inhibition.
Li R; Okada H; Yamashita T; Nio K; Chen H; Li Y; Shimakami T; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955438
[TBL] [Abstract][Full Text] [Related]
11. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of FoxM1 by MnSOD Overexpression Contributes to Cancer Stem-Like Cell Characteristics in the Lung Cancer H460 Cell Line.
Fu Z; Cao X; Yang Y; Song Z; Zhang J; Wang Z
Technol Cancer Res Treat; 2018 Jan; 17():1533033818789635. PubMed ID: 30111255
[TBL] [Abstract][Full Text] [Related]
13. Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features.
Kopanja D; Pandey A; Kiefer M; Wang Z; Chandan N; Carr JR; Franks R; Yu DY; Guzman G; Maker A; Raychaudhuri P
J Hepatol; 2015 Aug; 63(2):429-36. PubMed ID: 25828473
[TBL] [Abstract][Full Text] [Related]
14. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M
Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791
[TBL] [Abstract][Full Text] [Related]
15. Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.
Wang J; Zhang N; Han Q; Lu W; Wang L; Yang D; Zheng M; Zhang Z; Liu H; Lee TH; Zhou XZ; Lu KP
Cancer Lett; 2019 Mar; 444():82-93. PubMed ID: 30583078
[TBL] [Abstract][Full Text] [Related]
16. Silencing transcription factor FOXM1 represses proliferation, migration, and invasion while inducing apoptosis of liver cancer stem cells by regulating the expression of ALDH2.
Chen L; Wu M; Ji C; Yuan M; Liu C; Yin Q
IUBMB Life; 2020 Feb; 72(2):285-295. PubMed ID: 31580537
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 regulates glycolysis in hepatocellular carcinoma by transactivating glucose transporter 1 expression.
Shang R; Pu M; Li Y; Wang D
Oncol Rep; 2017 Apr; 37(4):2261-2269. PubMed ID: 28260073
[TBL] [Abstract][Full Text] [Related]
18. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers.
Liu J; Li J; Wang K; Liu H; Sun J; Zhao X; Yu Y; Qiao Y; Wu Y; Zhang X; Zhang R; Yang A
Signal Transduct Target Ther; 2021 Feb; 6(1):42. PubMed ID: 33526768
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of RhoGEF/RhoA alleviates regorafenib resistance and cancer stemness via Hippo signaling pathway in hepatocellular carcinoma.
Zhou HM; Chen DH; Diao WJ; Wu YF; Zhang JG; Zhong L; Jiang ZY; Zhang X; Liu GL; Li Q
Exp Cell Res; 2024 Mar; 436(1):113956. PubMed ID: 38341081
[TBL] [Abstract][Full Text] [Related]
20. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
